|
|
Search Results
|
New Search |
| These drugs include treatments for HIV-associated opportunistic infections and cancers (e.g., Pneumocystis jiroveci pneumonia and Kaposi's sarcoma), along with drugs used to treat other consequences of HIV infection and side effects of anti-HIV treatment. |
 FDA-approved Drugs |
 Opportunistic Infection and Other Drugs |
| A-56268 (Biaxin) |
| ACV (Zovirax) |
| Abbott-56268 (Biaxin) |
| Abelecet (Abelecet, AmBisome, Amphocin, Amphotec, Fungizone) |
| Aciclovir (Zovirax) |
| Acyclovir (Zovirax) |
| Acyclovir sodium (Zovirax) |
| Adefovir dipivoxil (Hepsera) |
| Adriablastin (Doxil) |
| Adriablastine (Doxil) |
| Adriamycin (Doxil) |
| Adriblastin (Doxil) |
| Aldesleukin (Proleukin) |
| Aldesleukina (Proleukin) |
| AmBisome (Abelecet, AmBisome, Amphocin, Amphotec, Fungizone) |
| Amphocin (Abelecet, AmBisome, Amphocin, Amphotec, Fungizone) |
| Amphotec (Abelecet, AmBisome, Amphocin, Amphotec, Fungizone) |
| Amphotericin B (Abelecet, AmBisome, Amphocin, Amphotec, Fungizone) |
| Amphotericin B lipid complex (Abelecet, AmBisome, Amphocin, Amphotec, Fungizone) |
| Androderm (Androderm, Androgel, Depo-Testosterone) |
| Androgel (Androderm, Androgel, Depo-Testosterone) |
| Ansamycin (Mycobutin) |
| Ansatipine (Mycobutin) |
| Arithromicina (Zithromax) |
| Azithromycin (Zithromax) |
| BAY 50-4798 (Proleukin) |
| BW 759 (Cytovene, Vitrasert) |
| BW-759 (Cytovene, Vitrasert) |
| Bactrim (Bactrim, Septra) |
| Baraclude (Baraclude) |
| Biaxin (Biaxin) |
| Biolf 62 (Cytovene, Vitrasert) |
| CaHA (Radiesse) |
| Caelyx (Doxil) |
| Calcium hydroxylapatite (Radiesse) |
| Carimune NF |
| Clarithromycin (Biaxin) |
| Copegus (Copegus, Rebetol, Virazole) |
| Cotrimoxazole (Bactrim, Septra) |
| Cytovene (Cytovene, Vitrasert) |
| Cytovene-IV (sodium salt) (Cytovene, Vitrasert) |
| Depo-Testosterone (Androderm, Androgel, Depo-Testosterone) |
| Diamidine (Nebupent) |
| Diflucan (Diflucan) |
| Doxil (Doxil) |
| Doxorubicin (liposomal) (Doxil) |
| Doxorubicin Hydrochloride (Doxil) |
| Doxorubicin hydrochloride (liposomal) (Doxil) |
| Doxorubicina (Doxil) |
| Dronabinol (Marinol) |
| EPO (Epogen, Procrit) |
| Entecavir (Baraclude) |
| Epoetin alfa (Epogen, Procrit) |
| Epoetin alpha (Epogen, Procrit) |
| Epoetina alfa (Epogen, Procrit) |
| Epogen (Epogen, Procrit) |
| Eprex (Epogen, Procrit) |
| Erythropoietin-alfa, recombinant (Epogen, Procrit) |
| Etopofos (Etoposide phosphosphate) (Etopophos (phosphate salt), Toposar, VePesid) |
| Etopophos (phosphate salt) (Etopophos (phosphate salt), Toposar, VePesid) |
| Etoposide (Etopophos (phosphate salt), Toposar, VePesid) |
| Etoposide phosphate (Etopophos (phosphate salt), Toposar, VePesid) |
| Fluconazol (Diflucan) |
| Fluconazole (Diflucan) |
| Fungizone (Abelecet, AmBisome, Amphocin, Amphotec, Fungizone) |
| GS-840 (Hepsera) |
| Gamimune N |
| Gammagard S/D |
| Gammar-P I.V. |
| Gamunex |
| Ganciclovir (Cytovene, Vitrasert) |
| Gancyclovir (Cytovene, Vitrasert) |
| Genotropin (Serostim) |
| Growth hormone (human) (Serostim) |
| Hepsera (Hepsera) |
| Human growth hormone (Serostim) |
| Humatrope (Serostim) |
| IFN (Intron A (2b), Roferon-A (2a)) |
| IGIV |
| IL-2 (Proleukin) |
| INH (Nydrazid) |
| IVIG |
| Immune Globulin Intravenous (Human) |
| Immune globulin |
| Interferon alfa-2 (Intron A (2b), Roferon-A (2a)) |
| Interleukin-2, recombinant human (Proleukin) |
| Intron A (2b) (Intron A (2b), Roferon-A (2a)) |
| Isoniazid (Nydrazid) |
| Isoniazida (Nydrazid) |
| Isonicotinic acid hydrazide (Nydrazid) |
| Itraconazol (Sporanox) |
| Itraconazole (Sporanox) |
| Iveegam EN |
| Lastet (Etopophos (phosphate salt), Toposar, VePesid) |
| Liposomal Amphotericin B (Abelecet, AmBisome, Amphocin, Amphotec, Fungizone) |
| Liposomal Doxorubicin (Doxil) |
| Lomidine (Nebupent) |
| Marinol (Marinol) |
| Megace ES (Megace ES, Megace Oral Suspension) |
| Megace Oral Suspension (Megace ES, Megace Oral Suspension) |
| Megestrol (Megace ES, Megace Oral Suspension) |
| Megestrol acetate (Megace ES, Megace Oral Suspension) |
| Mycobutin (Mycobutin) |
| Mysteclin-F (Abelecet, AmBisome, Amphocin, Amphotec, Fungizone) |
| NSC 141540 (Etopophos (phosphate salt), Toposar, VePesid) |
| Nebupent (Nebupent) |
| New-Fill (Sculptra) |
| Norditropin (Serostim) |
| Nutropin (Serostim) |
| Nutropin AQ (Serostim) |
| Nydrazid (Nydrazid) |
| Onxol (Onxol, Taxol) |
| PEG-Intron (2b) (PEG-Intron (2b), Pegasys (2a)) |
| PLA (Sculptra) |
| PLLA (Sculptra) |
| PMEA (Hepsera) |
| Paclitaxel (Onxol, Taxol) |
| Panglobulin |
| Paxene (Onxol, Taxol) |
| Pegasys (2a) (PEG-Intron (2b), Pegasys (2a)) |
| Peginterferon alfa-2 (PEG-Intron (2b), Pegasys (2a)) |
| Pentamidina (Nebupent) |
| Pentamidine (Nebupent) |
| Pentamidine isethionate (Nebupent) |
| Pentamidine mesylate (Nebupent) |
| Poly-L-lactic acid (Sculptra) |
| Polygam S/D |
| Preveon (Hepsera) |
| Procrit (Epogen, Procrit) |
| Proleukin (Proleukin) |
| RO 107-9070/194 (Valcyte) |
| RS-079070-194 (Valcyte) |
| RS-21592 (Cytovene, Vitrasert) |
| Radiance FN (Radiesse) |
| Radiesse (Radiesse) |
| Rebetol (Copegus, Rebetol, Virazole) |
| Recombinant interferon alfa-2a (Intron A (2b), Roferon-A (2a)) |
| Recombinant interferon alfa-2b (Intron A (2b), Roferon-A (2a)) |
| Recombinant interferon alpha-2a (Intron A (2b), Roferon-A (2a)) |
| Recombinant interferon alpha-2b (Intron A (2b), Roferon-A (2a)) |
| Ribamide (Copegus, Rebetol, Virazole) |
| Ribamidil (Copegus, Rebetol, Virazole) |
| Ribamidyl (Copegus, Rebetol, Virazole) |
| Ribavirin (Copegus, Rebetol, Virazole) |
| Ribavirina (Copegus, Rebetol, Virazole) |
| Ribovirin (Copegus, Rebetol, Virazole) |
| Rifabutin (Mycobutin) |
| Rifabutina (Mycobutin) |
| Rifabutine (Mycobutin) |
| Rifadin (Rifadin, Rimactane) |
| Rifadin IV (Rifadin, Rimactane) |
| Rifampicin (Rifadin, Rimactane) |
| Rifampicina (Rifadin, Rimactane) |
| Rifampin (Rifadin, Rimactane) |
| Rifamycin AMP (Rifadin, Rimactane) |
| Rimactane (Rifadin, Rimactane) |
| Roferon-A (2a) (Intron A (2b), Roferon-A (2a)) |
| Sculptra (Sculptra) |
| Septra (Bactrim, Septra) |
| Serostim (Serostim) |
| Somatropin (Serostim) |
| Somatropina (Serostim) |
| Sporanox (Sporanox) |
| Sulfamethoxazole/ Trimethoprim (Bactrim, Septra) |
| Sulfatrim (Bactrim, Septra) |
| Sumamed (Zithromax) |
| Sustanon (Androderm, Androgel, Depo-Testosterone) |
| TE-031 (Biaxin) |
| THC (Marinol) |
| TMP-SMX (Bactrim, Septra) |
| Taxol (Onxol, Taxol) |
| Taxol A (Onxol, Taxol) |
| Testoderm (Androderm, Androgel, Depo-Testosterone) |
| Testosterona (Androderm, Androgel, Depo-Testosterone) |
| Testosterone (Androderm, Androgel, Depo-Testosterone) |
| Tetrahydrocannabinol (Marinol) |
| Toposar (Etopophos (phosphate salt), Toposar, VePesid) |
| Tribavirin (Copegus, Rebetol, Virazole) |
| Trimethoprim (Bactrim, Septra) |
| UK-49858 (Diflucan) |
| VP 16213 (Etopophos (phosphate salt), Toposar, VePesid) |
| VP-16 (Etopophos (phosphate salt), Toposar, VePesid) |
| Valcyt (Valcyte) |
| Valcyte (Valcyte) |
| Valganciclovir (Valcyte) |
| Valganciclovir hydrochloride (Valcyte) |
| VePesid (Etopophos (phosphate salt), Toposar, VePesid) |
| Venoglobulin-S |
| Viramide (Copegus, Rebetol, Virazole) |
| Virazole (Copegus, Rebetol, Virazole) |
| Vitrasert (Cytovene, Vitrasert) |
| Zithromax (Zithromax) |
| Zorbtive (Serostim) |
| Zovirax (Zovirax) |
| delta9-THC (Marinol) |
| pegylated interferon (PEG-Intron (2b), Pegasys (2a)) |
| r-HuEPO (Epogen, Procrit) |
| r-hGH (Serostim) |
| rIL-2 (Proleukin) |
| Investigational Drugs |
| Opportunistic Infection and Other Drugs |
| AMP (Ampligen) |
| Acido valproico |
| Ampligen (Ampligen) |
| Atvogen (Ampligen) |
| BVM |
| Bevirimat |
| Depakene |
| Depakote |
| Divalproex sodium |
| PA 457 |
| PA-457 |
| PA457 cpd |
| Poly I:poly C12U (Ampligen) |
| Poly(I)-Poly(C12U) (Ampligen) |
| VPA |
| Valproate |
| Valproic acid |
| |
|
|
Drug News
- Important label update for Norvir (ritonavir) - November 24, 2009
- New dosing recommendations Retrovir (zidovudine) syrup for HIV-infected infants - November 10, 2009
- Clinical Trial of Antiretroviral-based HIV Prevention Strategies for Women Now Under Way - September 16, 2009
- FDA Issues a Safety Warning for Etravirine - August 26, 2009
- Phase III Clinical Trial Results show Carregeenan to be Safe but not Effective as a Vaginal Microbicide - February 18, 2008
- FDA Approves New NNRTI, Etravirine - January 18, 2008
- FDA Approves the First Integrase Inhibitor, Raltegravir - October 12, 2007
- FDA Antiviral Drugs Advisory Committee Recommends Accelerated Approval of Raltegravir - September 5, 2007
- FDA Approves HIV-Entry Inhibitor Maraviroc - August 6, 2007
|
|